Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGRM-001
- Development stage
- Phase 2
- Lead developer
- Next Generation Regenerative Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Subchondral
01
Overview
NGRM-001 is an investigational autologous cell-based therapy consisting of mesenchymal stem cells (MSCs) derived from bone marrow aspirate. Developed by Next Generation Regenerative Medicine, the therapy is primarily intended for the treatment of knee osteoarthritis. The treatment involves harvesting bone marrow aspirate from the patient's posterior superior iliac crest (often using the Marrow Cellutions system) and delivering the concentrated cells via a combination of intra-articular and subchondral injections. NGRM-001 leverages the regenerative, anti-inflammatory, and immunomodulatory properties of MSCs to promote tissue repair, modulate the joint's microenvironment, and alleviate chronic pain associated with degenerative joint disease. It is currently being evaluated in early-phase clinical trials to establish its safety and clinical efficacy.
- Other names
- Bone Marrow Derived Mesenchymal Stem CellsBone Marrow AspirateBMAMarrow Cellutions
Beyond the preview
Go deeper on NGRM-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGRM-001.